Ajay Sheshadri
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ajay Sheshadri.
JAMA | 2014
Mario Castro; Tonya S. King; Susan J. Kunselman; Michael D. Cabana; Loren C. Denlinger; Fernando Holguin; Shamsah Kazani; Wendy C. Moore; James N. Moy; Christine A. Sorkness; Pedro C. Avila; Leonard B. Bacharier; Eugene R. Bleecker; Homer A. Boushey; James F. Chmiel; Anne M. Fitzpatrick; Deborah A. Gentile; Mandeep Hundal; Elliot Israel; Monica Kraft; Jerry A. Krishnan; Craig LaForce; Stephen C. Lazarus; Robert F. Lemanske; Njira L Lugogo; Richard J. Martin; David T. Mauger; Edward T. Naureckas; Stephen P. Peters; Wanda Phipatanakul
IMPORTANCE In asthma and other diseases, vitamin D insufficiency is associated with adverse outcomes. It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and vitamin D insufficiency. OBJECTIVE To evaluate if vitamin D supplementation would improve the clinical efficacy of inhaled corticosteroids in patients with symptomatic asthma and lower vitamin D levels. DESIGN, SETTING, AND PARTICIPANTS The VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) randomized, double-blind, parallel, placebo-controlled trial studying adult patients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institutes AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by January 2014. After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized. INTERVENTIONS Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n = 201) or placebo (n = 207) was added to inhaled ciclesonide (320 µg/d). If asthma control was achieved after 12 weeks, ciclesonide was tapered to 160 µg/d for 8 weeks, then to 80 µg/d for 8 weeks if asthma control was maintained. MAIN OUTCOMES AND MEASURES The primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care). RESULTS Treatment with vitamin D3 did not alter the rate of first treatment failure during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjusted hazard ratio, 0.9 [95% CI, 0.6-1.3]). Of 14 prespecified secondary outcomes, 9 were analyzed, including asthma exacerbation; of those 9, the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control (111.3 µg/d [95% CI, 102.2-120.4 µg/d] in the vitamin D3 group vs 126.2 µg/d [95% CI, 117.2-135.3 µg/d] in the placebo group; difference of 14.9 µg/d [95% CI, 2.1-27.7 µg/d]). CONCLUSIONS AND RELEVANCE Vitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D insufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01248065.
Radiology | 2015
Robert P. Thomen; Ajay Sheshadri; James D. Quirk; Jim Kozlowski; Henry Ellison; Rhonda D. Szczesniak; Mario Castro; Jason C. Woods
PURPOSE To quantify regional lung ventilation in healthy volunteers and patients with severe asthma (both before and after thermoplasty) by using a combination of helium 3 ((3)He) magnetic resonance (MR) imaging and computed tomography (CT), with the intention of developing more effective image-guided treatments for obstructive lung diseases. MATERIALS AND METHODS With approval of the local institutional review board, informed consent, and an Investigational New Drug Exemption, six healthy volunteers and 10 patients with severe asthma were imaged in compliance with HIPAA regulations by using both multidetector CT and (3)He MR imaging. Individual bronchopulmonary segments were labeled voxel by voxel from the CT images and then registered to the (3)He MR images by using custom software. The (3)He signal intensity was then analyzed by evaluating the volume-weighted fraction of total-lung signal intensity present in each segment (segmental ventilation percentage [ SVP segmental ventilation percentage ]) and by identifying the whole-lung defect percentage and the segmental defect percentage. Of the 10 patients with asthma, seven received treatment with bronchial thermoplasty and were imaged with (3)He MR a second time. Changes in segmental defect percentages and whole-lung defect percentages are presented. RESULTS Ventilation measures for healthy volunteers yielded smaller segment-to-segment variation (mean SVP segmental ventilation percentage , 100% ± 18 [standard deviation]) than did the measures for patients with severe asthma (mean SVP segmental ventilation percentage , 97% ± 23). Patients with asthma also demonstrated larger segmental defect percentages (median, 13.5%; interquartile range, 8.9%-17.8%) than healthy volunteers (median, 6%; interquartile range, 5.6%-6.3%). These quantitative results confirm what is visually observed on the (3)He images. A Spearman correlation of r = -0.82 was found between the change in whole-lung defect percentage and the number of days between final treatment and second (3)He imaging. CONCLUSION Regional quantification of lung ventilation is indeed feasible and may be a useful technique for image-guided treatment of obstructive lung diseases, such as bronchial thermoplasty for severe asthma. In these patients, ventilation defects decreased as a function of time after treatment.
Clinics in Chest Medicine | 2013
Ajay Sheshadri; Mario Castro; Alexander Chen
This article presents an overview of bronchial thermoplasty, a novel treatment for severe asthma. Within, the authors discuss the rationale for bronchial thermoplasty in severe asthma, current clinical evidence for the use of this procedure, clinical recommendations, and future directions.
European Respiratory Journal | 2017
Rachid Berair; Ruth Hartley; Vijay Mistry; Ajay Sheshadri; Sumit Gupta; Amisha Singapuri; Sherif Gonem; Richard P. Marshall; Ana R. Sousa; Aarti Shikotra; Richard Kay; Andrew J. Wardlaw; Peter Bradding; Salman Siddiqui; Mario Castro; Christopher E. Brightling
Airway remodelling in asthma remains poorly understood. This study aimed to determine the association of airway remodelling measured on bronchial biopsies with 1) lung function impairment and 2) thoracic quantitative computed tomography (QCT)-derived morphometry and densitometry measures of proximal airway remodelling and air trapping. Subjects were recruited from a single centre. Bronchial biopsy remodelling features that were the strongest predictors of lung function impairment and QCT-derived proximal airway morphometry and air trapping markers were determined by stepwise multiple regression. The best predictor of air trapping was validated in an independent replication group. Airway smooth muscle % was the only predictor of post-bronchodilator forced expiratory volume in 1 s (FEV1) % pred, while both airway smooth muscle % and vascularity were predictors of FEV1/forced vital capacity. Epithelial thickness and airway smooth muscle % were predictors of mean segmental bronchial luminal area (R2=0.12; p=0.02 and R2=0.12; p=0.015), whereas epithelial thickness was the only predictor of wall area % (R2=0.13; p=0.018). Vascularity was the only significant predictor of air trapping (R2=0.24; p=0.001), which was validated in the replication group (R2=0.19; p=0.031). In asthma, airway smooth muscle content and vascularity were both associated with airflow obstruction. QCT-derived proximal airway morphometry was most strongly associated with epithelial thickness and airway smooth muscle content, whereas air trapping was related to vascularity. Airway remodelling in asthma biopsies is associated with proximal airway QCT-derived morphometry and air trapping http://ow.ly/ucoA308Jv9F
Journal of Computer Assisted Tomography | 2015
Ajay Sheshadri; Alfonso Rodriguez; Ryan Chen; James Kozlowski; Dana Burgdorf; Tammy Koch; Jaime Tarsi; Rebecca Schutz; Brad Wilson; Kenneth B. Schechtman; Joseph K. Leader; Eric A. Hoffman; Mario Castro; Sean B. Fain; David S. Gierada
Objective We reduced the computed tomography (CT)–reconstructed field of view (FOV), increasing pixel density across airway structures and reducing partial volume effects, to determine whether this would improve accuracy of airway wall thickness quantification. Methods We performed CT imaging on a lung phantom and 29 participants. Images were reconstructed at 30-, 15-, and 10-cm FOV using a medium-smooth kernel. Cross-sectional airway dimensions were compared at each FOV with repeated-measures analysis of variance. Results Phantom measurements were more accurate when FOV decreased from 30 to 15 cm (P < 0.05). Decreasing FOV further to 10 cm did not significantly improve accuracy. Human airway measurements similarly decreased by decreasing FOV (P < 0.001). Percent changes in all measurements when reducing FOV from 30 to 15 cm were less than 3%. Conclusions Airway measurements at 30-cm FOV are near the limits of CT resolution using a medium-smooth kernel. Reducing reconstructed FOV would minimally increase sensitivity to detect differences in airway dimensions.
The Journal of Allergy and Clinical Immunology | 2014
Ajay Sheshadri; Eric A. Hoffman; Mario Castro
Subjects with uncontrolled asthma account for the majority of health care costs attributed to asthma. New approaches are needed to properly characterize asthma phenotypes to capture the complexity of this disease. The term ‘‘endotype’’ was coined by Anderson as a way to classify subtypes of asthma that differ functionally and pathologically on a molecular level. Cluster analyses have been performed in adults and children that have identified distinct clinical phenotypes of asthma that differ in patient characteristics, lung function, health care use, and medication use, but further work needs to be done to better define biomarkers that can easily classify these patients and guide therapy. Quantitative computed tomographic (CT) imaging is emerging as a useful tool in the study of asthma that can assist in the phenotyping of the disease and offers a unique wealth of objectively determined structural and functional information not readily available through traditional measures. CT measures of airway wall remodeling correlate well with lung function, asthma severity, and histologic airway wall remodeling. Lung densitometry can identify severe asthma phenotypes associated with increased health care use, and a decrease in air trapping is associated with improvement in lung function. Fractal analysis of the airway tree offers an assessment of structural complexity, which is often reduced in asthmatic patients. These quantitative CT measures each contribute to the characterization of the asthmatic patient in unique ways that build on the information gained by traditional sputum and blood biomarkers. In this issue of the Journal, Gupta et al apply cluster analytic
Academic Radiology | 2014
Chad A. Witt; Ajay Sheshadri; Luke Carlstrom; Jaime Tarsi; James Kozlowski; Brad Wilson; David S. Gierada; Eric A. Hoffman; Sean B. Fain; Janice Cook-Granroth; Geneline Sajol; Oscar L. Sierra; Tusar K. Giri; Michael O'Neill; Jie Zheng; Kenneth B. Schechtman; Leonard B. Bacharier; Nizar N. Jarjour; William W. Busse; Mario Castro
Current Allergy and Asthma Reports | 2014
Ajay Sheshadri; Matthew McKenzie; Mario Castro
Archive | 2015
Kaharu Sumino; John Cochran; Ajay Sheshadri; Mario Castro
American Journal of Respiratory and Critical Care Medicine | 2015
Kaharu Sumino; Ajay Sheshadri; Mario Castro